Latest in Cardiology from ACC.org
- Disparities in Hypertension Across Age Spectrum Among Asian American Adults: The Power of Data DisaggregationThere is an increasing appreciation of the racial differences in cardiovascular disease (CVD) risk profiles and subsequent outcomes. This recognition has led to meaningful changes in clinical practice, such as screening for diabetes mellitus earlier...
- ACCEL Lite: STRIDE Trial: Effects of Semaglutide in Patients With Peripheral Artery DiseaseIn this interview, Drs. Alison Bailey and Marc Bonaca discuss how the STRIDE trial data supports the use of semaglutide for individuals with PAD and type 2 diabetes, highlighting its cardiometabolic, cardiovascular, and kidney benefits, as well as its ability to improve function, symptoms, and overall quality of life.
- AHA Scientific Statement Update on Kawasaki Disease: Identifying and Managing Patients at High RiskThere have been significant advances in the understanding of Kawasaki disease (KD) since the first published report in 1967. The recently published 2024 American Heart Association scientific statement reviews the latest evidence and expert consensus since the prior version in 2017...
- FDA Update: Abbott Removes HeartMate Mobile Power UnitThe U.S. Food and Drug Administration (FDA) announced on April 24 that Abbott has removed the HeartMate Mobile Power Unit, used with HeartMate II and HeartMate 3 Left Ventricular Assist Systems, due to reports of sudden, unexpected power loss.
- FINEARTS-HF: Finerenone Improves Outcomes Regardless of Baseline Kidney RiskFinerenone was found to consistently improve clinical outcomes as well as heart failure (HF)-related health status and albuminuria, in patients with HF with mildly reduced ejection fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF) regardless of baseline kidney risk...